Prevalence and Distribution of MethicillinـResistant Staphylococcus aureus in Clinical Samples from Patients in Diyala Province Hospitals
DOI:
https://doi.org/10.46966/msjar.v6i3.295Keywords:
MethicillinـResistant, Staphylococcus aureus, MRSA, throatـswabsAbstract
Background: Methicillinـresistant Staphylococcus. aureus (M.R.S.A) strains have emerged as an emerging worldwide healthcare problem, as well as Staphylococcus aureus is a prominent human pathogenic organism that causes a broad spectrum of diseases. It is essential to comprehend the allocation as well as the frequency of M.R.S.A in various medical specimens to direct antibacterial management initiatives as well as focused therapies. Objectives: The purpose of the present research was to examine the incidence as well as distribution of antibioticـresistant strains of S. aureus, including MRSA, that were isolated from a variety of medical samples obtained from hospitalizedـpatients inside DiyalaـIraq, including throatـswabs, urineـspecimens, woundـswabs, as well as burnـspecimens. Methods: A total of 301 medical specimens were gathered between September 2024 and January 2025. The VITEKـ2 automatedـsystem, as well as conventional microbiology methods, have been utilized to isolate, identify, as well as analyze for resistance to antibiotics among bacteria. Results: Out of the 301 clinical samples, 56 (18.60%) showed positive results for S.aureus, with the highest prevalence observed in throat swabs (21.05%) and burn samples (21.88%). Antimicrobial susceptibility testing revealed high rates of resistance to various antibiotic classes, including universal resistance (100%) against βـlactams (penicillins & cephalosporins). Macrolides (erythromycin) as well as lincosamides (clindamycin) also exhibited high resistance rates (78.6% as well as 73.2%, respectively), particularly in throat and wound isolates. Glycopeptides (vancomycin) demonstrated strong efficacy, with 100% susceptibility in throat as well as urine isolates, though worrisome intermediate resistance (28.6%) was detected in burn samples as well as full resistance (18.2%) in wound isolates. Fluoroquinolones (ciprofloxacin, levofloxacin) showed variable resistance (48.2% overall), with urine isolates displaying higher susceptibility (61.1%) but wound isolates exhibiting strong resistance (63.6%). Notably, last-resort antibiotics (tigecycline, linezolid) remained 100% effective across all isolates. Conclusion: The epidemiological study of S.aureus, including M.R.S.A, in hospitalized individuals in DiyalaـIraq, is better understood thanks to the current research. The substantial threat this infection poses to the community's safety is highlighted through the widespread distribution of antibioticـresistant strains, the appearance of vancomycinـintermediate as well as resistantـisolates, as well as the coـexistence of many M.R.S.Aـlineages.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Falah H. Abbas, Adnan H. Aubaid

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















